Breaking News Instant updates and real-time market news.

OCLR

Bought by LITE

$0.00

(0.00%)

, FNSR

Finisar

$21.59

0.2 (0.94%)

06:17
01/11/19
01/11
06:17
01/11/19
06:17

Polish authorities detain Huawei sales director, WSJ reports

Polish authorities detained and charged the sales director of Huawei's local office, a Chinese national, for allegedly conducting high-level espionage on behalf of a Chinese spy agency, The Wall Street Journal reports. According to reports, Huawei accounted for nearly 17% of Lumentum's (LITE) sales in FY17, about 15% of FY17 sales for Oclaro (OCLR) and 11% of FY17 sales for Finisar (FNSR). The company competes in China with ZTE (ZTCOY), Infinera (INFN) and Ciena (CIEN). Reference Link

OCLR

Bought by LITE

$0.00

(0.00%)

FNSR

Finisar

$21.59

0.2 (0.94%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

INFN

Infinera

$4.36

0.04 (0.93%)

CIEN

Ciena

$36.90

0.33 (0.90%)

  • 25

    Feb

OCLR Bought by LITE
$0.00

(0.00%)

12/17/18
NEED
12/17/18
NO CHANGE
Target $75
NEED
Strong Buy
Lumentum can continue posting 'beat and raise' quarters, says Needham
Needham analyst Alex Henderson left recent meetings with management with a "strong conviction" that Lumentum can continue to post "beat and raise" quarters. With the Oclaro deal closed, the analyst increased his estimates for Lumentum to reflect the combined company numbers. He believes the company looks well positioned and keeps a Strong Buy rating on the shares with a $75 price target.
12/06/18
MKMP
12/06/18
DOWNGRADE
MKMP
Neutral
Finisar downgraded to Neutral from Buy at MKM Partners
MKM Partners analyst Michael Genovese downgraded Finisar (FNSR) to Neutral from Buy with a price target of $24 after its merger agreement with II-VI (IIVI) announced last month. The analyst further notes that Q4 is trending well for the optical components group which also includes Lumentum (LITE) and Oclaro (OCLR), but believes that the guidance for March will be "sequentially down due to annual price negotiations and Chinese New Year".
11/13/18
PIPR
11/13/18
NO CHANGE
Target $72
PIPR
Overweight
Piper remains buyer of Lumentum following yesterday's 33% decline
Piper Jaffray analyst Troy Jensen remains a buyer of Lumentum (LITE) shares following yesterday's 33% decline. The reduced forecast at Apple (AAPL) has nothing to do with lost share for Lumentum, rather it is more indicative of lower sales forecasts at this key account, Jensen tells investors in a research note. The analyst continues to believe the 3D sensing market "will grow handsomely" with Apple and he notes that Android phones are just beginning their adoption. He also sees a pending opportunity for world facing 3D sensing applications. Further, the core telco optics market is in the early innings of an upgrade cycle, which should provide a "nice tailwind" for Lumentum, says Jensen. He also thinks the pending acquisition of Oclaro (OCLR) could also be a catalyst for the shares given the earnings accretion once the merger gets approval. The analyst lowered his price target for Lumentum to $72 from $85 and reiterates an Overweight rating on the name.
11/12/18
CHLM
11/12/18
DOWNGRADE
Target $24
CHLM
Hold
Finisar downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Richard Shannon downgraded Finisar (FNSR) to Hold from Buy and raised his price target on the shares to $24 from $23. The analyst believes that II-VI's (IIVI) $26/share cash and stock offer for the company, which was a 38% premium to the close on November 8th, is more than a fair deal, given that Lumentum's (LITE) offer premium for Oclaro (OCLR) earlier this year was 27%. Shannon has some doubts about whether this deal will close given the Lumentum/Oclaro deal has not yet closed and the intensifying political standoff between the US and China, but also admits II-VI and Finisar would not have agreed to this deal if there was not a good chance of closing.
FNSR Finisar
$21.59

0.2 (0.94%)

12/18/18
PIPR
12/18/18
NO CHANGE
PIPR
Cisco's Luxtera deal negative for Finisar and Applied Opto, says Piper Jaffray
Piper Jaffray analyst James Fish notes that the $660M acquisition of Luxterra announced by Cisco (CSCO) yesterday will have "mostly negative" impact on datacom focused optical transceiver suppliers Finisar (FNSR) and Applied Optoelectronics (AAOI). For the former, the analyst notes that Finisar generates about 75% of revenues from datacom transceivers and has frequently experienced Cisco as a 10% plus customer, adding that the vertical integration of the deal will diminishing Cisco's need for merchant transceivers. For the latter, the analyst notes that while Applied Optoelectronics does not "directly sell these components", the Luxterra deal shrinks its market and may lead to more aggressive price moves by the competitors. Fish also sees Fabrinet (FN) as a direct beneficiary of the Luxterra deal given its position as its contract manufacturer that stands to benefit "as Cisco ramps production of SiP transceivers."
12/18/18
RILY
12/18/18
NO CHANGE
RILY
Luxtera buyout negative for Finisar, Applied Optoelectronics, says B. Riley FBR
B. Riley FBR analyst Dave Kang views Cisco Systems' (CSCO) acquisition of Luxtera as a negative for Finisar (FNSR) and Applied Optoelectronics (AAOI). The analyst has Neutral ratings on both stocks.
12/18/18
LOOP
12/18/18
NO CHANGE
Target $23
LOOP
Hold
Finisar price target raised to $23 from $20 at Loop Capital
Loop Capital analyst James Kisner raised his price target on Finisar (FNSR) to $23, reflecting the "approximate value of the total consideration" that its shareholders will receive in the "very accretive" acquisition by II-VI Incorporated (IIVI). The analyst also lowers Finisar's FY20 EPS view to $1.06 from $1.71 and keeps his Hold rating on the stock, citing a "more conservative approach" in his forecasts for 3D sensing and "200G/400G datacom".
12/31/18
12/31/18
UPGRADE
Target $40

Outperform
II-VI upgraded to Outperform on valuation at Northland
As previously reported, Northland upgraded II-VI (IIVI) to Outperform from Market Perform and increased its price target to $40 from $39. Analyst Tim Savageaux said the pullback in shares following the Finisar (FNSR) discounts an overly negative view given both pro forma earnings power and deal synergies of nearly $4/share.
ZTCOY ZTE Corp.
$0.00

(0.00%)

08/16/18
RILY
08/16/18
NO CHANGE
Target $50
RILY
Buy
Fabrinet price target raised to $50 from $40 at B. Riley FBR
B. Riley FBR analyst Dave Kang maintained a Buy rating on Fabrinet (FN) and raised his price target for shares to $50 from $40 ahead of the company's Q4 earnings on August 20, which he expects will be above consensus, as the latest industry data indicates that optical demand continues to improve after a 2017 correction. Kang says he remains a buyer into the print, and that Fabrinet should get a boost with the ban on ZTE (ZTCOY) lifted.
08/23/18
PIPR
08/23/18
UPGRADE
Target $46
PIPR
Overweight
Acacia Communications upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Troy Jensen upgraded Acacia Communications (ACIA) to Overweight and raised his price target for the shares to $46 from $38. Demand for optical is improving and Acacia is the best way to play the upcoming 400G cycle, Jensen tells investors in a research note. He believes the company's revenue growth will accelerate amid easy comps, improving demand from ZTE (ZTCOY), recent design wins and upcoming product cycles. Acacia can return to profitability levels seen before the China/ZTE slowdown, the analyst contends.
08/23/18
PIPR
08/23/18
UPGRADE
Target $26
PIPR
Overweight
Finisar upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Troy Jensen upgraded Finisar (FNSR) to Overweight from Neutral and raised his price target for the shares to $26 from $18. The shares closed yesterday down 95c, of 5%, to $18.65. China demand is returning via Huawei and ZTE (ZTCOY), Finisar is facing easy comps following five quarters of depressed demand and the upcoming 400G cycle should provide a tailwind in 2019, Jensen tells investors in a research note. On top of improving optical industry dynamics, the analyst believes Finisar's new CEO will improve the cost structure and execution at the company and drive better profitability. Now is a "great time" to revisit owning the shares, Jensen contends. The analyst this morning also upgraded Acacia Communications (ACIA) to Overweight from Neutral.
08/31/18
ROTH
08/31/18
NO CHANGE
Target $7
ROTH
Buy
Roth Capital encouraged by good reviews for Pixelworks-powered Axon 9
Roth Capital analyst Suji Desilva said he was encouraged by positive reviews for ZTE's (ZTCOY) Axon 9 smartphone, which uses Pixelworks' (PXLW) Iris mobile processor. Of note, reviews have emphasized the high aspect ratio OLED display and viewing quality, affirming his constructive thesis on the value of Pixelworks' core video technology, Desilva tells investors. He raised his price target on Pixelworks shares to $7 from $6 and maintains a Buy rating on the stock.
INFN Infinera
$4.36

0.04 (0.93%)

11/13/18
MSCO
11/13/18
DOWNGRADE
Target $6
MSCO
Equal Weight
Infinera downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Meta Marshall downgraded Infinera to Equal Weight and lowered his price target for the shares to $6 from $9.50.
11/13/18
MSCO
11/13/18
DOWNGRADE
Target $6
MSCO
Equal Weight
Infinera downgraded to Equal Weight after analyst day delay at Morgan Stanley
As previously reported, Morgan Stanley analyst Meta Marshall downgraded Infinera to Equal Weight from Overweight as she sees "no reason to race in" until there are signs that the revenue base has stabilized. The company's recent earnings report revealed that the Coriant business is in worse condition than expected, noted Marshall, who believes the company's postponement of its analyst day leaves few opportunities for a positive rerating in the next 6 months. Marshall lowered her price target on Infinera shares to $6.00 from $9.50 after lowering her 2021 EPS estimate to 40c-60c from the 75c-$1.00 she'd estimated earlier.
11/13/18
11/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lumentum (LITE) downgraded to Neutral from Overweight at JPMorgan with analyst Samik Chatterjee saying yesterday's negative pronouncement underscored the challenges likely to be faced by Apple (AAPL) supply chain companies in delivering to investor expectations as Apple continues to prioritize its premium pricing strategy on iPhones relative to volumes. 2. Best Buy (BBY) downgraded to Neutral from Buy at BofA/Merrill with analyst Curtis Nagle citing expectations for slowing industry growth, difficult comps in key products and cost inflation. 3. Perrigo (PRGO) downgraded to Hold from Buy at Berenberg with analyst Patrick Trucchio saying although the key reason to own Perrigo shares remains intact, namely the U.S. government's push to shift more products from prescription to nonprescription, "too much uncertainty in generics has placed us on the sidelines." 4. Sabra Health Care (SBRA) downgraded to Neutral from Buy at Mizuho with analyst Richard Anderson saying he wants to a take a "pause" until the earnings reset from the "surprise news" of Senior Care stopping rent payments since May becomes better understood. 5. Infinera (INFN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Meta Marshall saying she sees "no reason to race in" until there are signs that the revenue base has stabilized. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/18
JEFF
11/09/18
UPGRADE
Target $5
JEFF
Hold
Infinera upgraded to Hold from Underperform at Jefferies
Jefferies analyst George Notter upgraded Infinera to Hold while lowering his price target for the shares to $5 from $7.75. The analyst cites valuation for the upgrade following this week's post-earnings selloff.
CIEN Ciena
$36.90

0.33 (0.90%)

12/14/18
BMOC
12/14/18
NO CHANGE
Target $42
BMOC
Outperform
Ciena price target raised to $42 from $36 at BMO Capital
BMO Capital analyst Tim Long raised his price target on Ciena to $42 after its "strong" Q4 results that were driven by improving margins, saying the company continues to "diversify away from the traditional telco vertical into growth areas like webscale, where demand is strong. " The analyst also keeps his Outperform rating on Ciena while citing the company's "growth outlook, improving balance sheet, and consistent capital return program."
12/14/18
LOOP
12/14/18
DOWNGRADE
Target $36
LOOP
Hold
Ciena downgraded to Hold from Buy at Loop Capital
Loop Capital analyst James Kisner downgraded Ciena to Hold from Buy, stating that while its 2019 revenue guidance was above consensus he thinks the rest of guidance, with gross margin below consensus, implied roughly in-line Q1 EPS. He stills views the company as very well positioned in the optical systems market, but sees the stock as close to fully valued, Kisner tells investors. He maintains a $36 price target on Ciena shares.
12/14/18
ARGS
12/14/18
NO CHANGE
Target $42
ARGS
Buy
Ciena price target raised to $42 from $38 at Argus
Argus analyst James Kelleher raised his price target on Ciena to $42 and kept his Buy rating after its Q4 earnings beat and the management's guidance of at least 20% EPS growth over the next 3 years. The analyst notes that growth rate being "much faster than the historical trend and the outlook for its pees", adding that the company also has no "direct" exposure to the China slowdown as it looks to build market share profitably and with no pricing erosion.
12/14/18
MKMP
12/14/18
NO CHANGE
Target $45
MKMP
Buy
Ciena price target raised to $45 from $38 at MKM Partners
MKM Partners analyst Michael Genovese raised his price target on Ciena to $45 after its "strong" Q4 results, saying the stock is a "must own" in the communications equipment sector. The analyst cites the company producing "another record quarter for orders, with book-to-bill well above 1.0", along with a 12% increase in its backlog in Q4, while its FY18 top-line grew by 10% in a market where revenues grew by mid-single digits. Genovese keeps his Buy rating on Ciena, stating that its market share gains are driven by its "best technology" and trust from its Tier 1 customers.

TODAY'S FREE FLY STORIES

CYTK

Cytokinetics

$6.83

-0.19 (-2.71%)

07:43
01/22/19
01/22
07:43
01/22/19
07:43
Hot Stocks
Cytokinetics announces FDA feedback for potential reldesemtiv program »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$22.94

0.99 (4.51%)

, FISV

Fiserv

$77.83

3.23 (4.33%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Downgrade
First Data, Fiserv rating change  »

First Data downgraded to…

FDC

First Data

$22.94

0.99 (4.51%)

FISV

Fiserv

$77.83

3.23 (4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SAIC

SAIC

$66.03

0.38 (0.58%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Conference/Events
SAIC management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

PSEC

Prospect Capital

$6.74

0.04 (0.60%)

07:41
01/22/19
01/22
07:41
01/22/19
07:41
Downgrade
Prospect Capital rating change  »

Prospect Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$18.21

0.7 (4.00%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Downgrade
GasLog rating change  »

GasLog downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

OFG

OFG Bancorp

$18.14

0.19 (1.06%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Earnings
OFG Bancorp reports Q4 EPS 45c, consensus 42c »

Net income available to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 07

    Feb

  • 27

    Feb

07:40
01/22/19
01/22
07:40
01/22/19
07:40
General news
Treasury Market Outlook: Treasury yields are lower in risk-off trades »

Treasury Market Outlook:…

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:39
01/22/19
01/22
07:39
01/22/19
07:39
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$5.53

-0.12 (-2.12%)

07:38
01/22/19
01/22
07:38
01/22/19
07:38
Hot Stocks
Translate Bio announces clinical hold on MRT5201 IND application from FDA »

Translate Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$4.42

-0.25 (-5.35%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
Insys Therapeutics initiated  »

Insys Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCM

R1 RCM

$8.32

0.16 (1.96%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
R1 RCM initiated  »

R1 RCM initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$49.23

0.76 (1.57%)

07:36
01/22/19
01/22
07:36
01/22/19
07:36
Recommendations
Intel analyst commentary  »

Intel Q4 results should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

ONCS

OncoSec

$0.71

0.0134 (1.93%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Conference/Events
OncoSec management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

D

Dominion

$68.75

-0.15 (-0.22%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Downgrade
Dominion rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 10

    Feb

UBSH

Union Bankshares

$32.50

0.14 (0.43%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Earnings
Union Bankshares reports Q4 ex-items EPS 70c, consensus 68c »

Q4 net charge-offs were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 11

    Feb

JD

JD.com

$23.25

1.12 (5.06%)

, INTC

Intel

$49.23

0.76 (1.57%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

JD

JD.com

$23.25

1.12 (5.06%)

INTC

Intel

$49.23

0.76 (1.57%)

WYNN

Wynn Resorts

$115.19

0.94 (0.82%)

NKE

Nike

$80.45

1.33 (1.68%)

CRON

Cronos Group

$14.89

1.25 (9.16%)

MGM

MGM Resorts

$28.55

0.83 (2.99%)

AUY

Yamana Gold

$2.31

-0.12 (-4.94%)

UAA

Under Armour

$20.50

0.47 (2.35%)

I

Intelsat

$21.15

-1.26 (-5.62%)

APC

Anadarko

$48.68

0.61 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 06

    Feb

  • 10

    Feb

  • 13

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

INCY

Incyte

$78.44

-0.22 (-0.28%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Hot Stocks
Incyte treats first patient in Phase 3 clinical trial of itacitinib »

Incyte Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

AMBR

Amber Road

$8.45

0.19 (2.30%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Hot Stocks
Amber Road confirms receipt of director nominations from Altai Capital »

Amber Road confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 11

    Feb

CORV

Correvio

$3.24

0.365 (12.70%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Recommendations
Correvio analyst commentary  »

Correvio to unlock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBSV

ObsEva

$13.72

0.22 (1.63%)

07:33
01/22/19
01/22
07:33
01/22/19
07:33
Conference/Events
ObsEva management to meet with Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TGP

Teekay LNG

$12.80

0.23 (1.83%)

07:33
01/22/19
01/22
07:33
01/22/19
07:33
Upgrade
Teekay LNG rating change  »

Teekay LNG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABO

Cable One

$850.40

8.96 (1.06%)

07:32
01/22/19
01/22
07:32
01/22/19
07:32
Upgrade
Cable One rating change  »

Cable One upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRDCY

Bridgestone

$0.00

(0.00%)

07:32
01/22/19
01/22
07:32
01/22/19
07:32
Downgrade
Bridgestone rating change  »

Bridgestone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$0.75

0.0001 (0.01%)

, EW

Edwards Lifesciences

$168.41

9.29 (5.84%)

07:31
01/22/19
01/22
07:31
01/22/19
07:31
Hot Stocks
Neovasc announces dismissal of claim brought by Edwards Lifesciences »

Neovasc (NVCN) announced…

NVCN

Neovasc

$0.75

0.0001 (0.01%)

EW

Edwards Lifesciences

$168.41

9.29 (5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

STT

State Street

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Downgrade
State Street rating change  »

State Street downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.